MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third independent safety review: DSMB recommended continuation without modification.Completed Oral Presentation at Digestive Disease Week (DDW): Evaluation of the Safety and Efficacy of Eflornithine (Difluoro

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its third pre-specified safety

MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21, 2024. The work reflects the Company's on-going collaboration with Vanderbilt University Medical Center. "Gastric adenocarcinoma is the fifth leading global cause of cancer mortality and leading infection-associated cancer. In the U.S., gastric adenocarcinoma represents a major cancer disparity, with incidence rates 2-3 times or more greater in all non-white populations. Pa

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. Q1 2024 and recent Highlights: Clinical Announced revised timing for the interim data analysis for its ongoing ASPIRE trial, evaluating ivospemin (SBP-101) in combination with standard-of-care for metastatic pancreatic ductal adenocarcinoma (mPDAC). The analysis is now expected in Q1 2025 due to a l

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled "EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION". These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi. The product was developed in collaboration with Sanofi, an innovative global healthcare company. Flynpovi is Panbela's lead investigational product for the treatment of patien

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 195310Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/49978 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 49978Webcast Replay: 

MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2023 and Recent Highlights Collaborations Divestiture of assets within eflornithine (DFMO) pediatric neuroblastoma program to US WorldMeds® for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. Clinical The independent Data Safety Monitor

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 9, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date:  November 9, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 100225International: 973-528-0011; Code: 100225Webcast: https://www.webcaster4.com/Webcast/Page

MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 10, 2023, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023. Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.Date: Thursday, August 10, 2023Time: 4:30 PM Eastern TimeParticipant Numbers: Toll Free: 888-506-0062; Code: 681215International: 973-528-0011; Code: 681215Webcast: https://www.webcaster4.com/Webca

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 4, 2023, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: Thursday, May 04, 2023 Time: 4:30 PM Eastern Time Participant Numbers: Toll Free: 888-506-0062; Code: 130038 International: 973-528-0011; Code: 130038 Webcast: https://www.webcaster4.com/W

MINNEAPOLIS, March 08, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 16, 2023, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2022. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 116790Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/47782 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 47782Webca

MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 10, 2022, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November 10, 2022Time: 4:30 PM Eastern Time Participant Numbers:Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 598956 Webcast Link: h

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.48) by 54.05 percent.

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

Panbela Therapeutics (OTC:PBLA) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:10 PM. Here's what investors need to know about the announcement. Earnings Panbela Therapeutics missed estimated earnings by -171.0%, reporting an EPS of $-65.9 versus an estimate of $-24.34. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.36 which was followed by a 3.0% increase in the share price the next day. To track all earnings releases for Panbela Therapeutics visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate of $(24.34) by 170.75 percent.

Panbela Therapeutics (NASDAQ:PBLA) is set to give its latest quarterly earnings report on Tuesday, 2024-03-26. Here's what investors need to know before the announcement. Analysts estimate that Panbela Therapeutics will report an earnings per share (EPS) of $-24.34. Panbela Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.36, which was followed

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. ProSomnus, Inc. (NASDAQ:OSA) On Feb. 22, ProSomnus reported successful pilot study validation of next generation remote patient m